Lilly and Novo share GLP-1 longevity data
Pharma has the podium as Novo and Lilly stop talking about GLP-1 longevity and start measuring it, bringing early aging data to ARDD. AstraZeneca, Novartis, Novo (formally Novo Nordisk) and Eli Lilly all spoke from the platform at this year’s ARDD at Harvard. Novo and Lilly each showed early w
<p>Pharma has the podium as Novo and Lilly stop talking about GLP-1 longevity and start measuring it, bringing early aging data to ARDD. AstraZeneca, Novartis, Novo (formally Novo Nordisk) and Eli Lilly all spoke from the platform at this year’s ARDD at Harvard. Novo and Lilly each showed early w</p>